Idelalisib in relapsed indolent lymphoma

Dr Ajay Gopal of the Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, USA and colleagues have reported results from an international non-randomised phase II study of idelalisib monotherapy in patients with indolent non-Hodgkin's lymphoma. The overall response rate was impressive 57%, with a median progression-free survival of 11 months, values suggesting that the efficacy of idelalisib is similar or superior to those of other active treatment options in relapsed or refractory indolent non-Hodgkin's lymphoma. Read more here.